Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective treatments for type 2 diabetes (T2DM), obesity, and cardiovascular disease.1–3 Beyond these indications, they have shown promising clinical efficacy in conditions such as chronic kidney disease, metabolic dysfunction–associated steatohepatitis, obstructive sleep apnea, and Parkinson’s disease.4–6 With proven efficacy and increasing global use, there is a growing need … Read more